Receiving statin treatment for five years or more is associated with a 21% reduced risk of primary glaucoma, research has shown.
Patients with type 2 diabetes mellitus and chronic kidney disease have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.
Patients who underwent knee replacement who used an app to monitor their analgesic use had better pain control and took fewer opioids post surgery, study results show.
Concerns raised over non-medical alprazolam useSubscription
The benzodiazepine alprazolam is being obtained for non-medical use in the UK, particularly among young people, a survey has found.
Certain individuals at high risk of developing type 1 diabetes mellitis can delay progression to clinical disease by two years or more with a two-week course of teplizumab, according to a phase II study Source: Shutterstock.com
Vitamin D supplementation is not associated with a reduced risk of major cardiovascular events, a meta-analysis suggests.
People who take methadone use fewer illicit opioids when galantamine is added to their therapy, research shows.
Prednisolone reduces hand osteoarthritis pain Subscription
Patients with hand osteoarthritis experienced improvements in pain and function with low-dose prednisolone treatment, according to a study presented at the European Congress of Rheumatology.
The ketamine-related nasal spray esketamine is effective at relieving the symptoms of treatment-resistant depression, a phase III study has shown.
Regular consultations with pharmacists lead to improved medicine adherence in people with chronic heart failure, research results show.
National reporting and incentive schemes, such as the Quality and Outcomes Framework, have not prevented suboptimal management of heart failure in the UK, research published in PLoS Medicine has concluded.
A previously demonstrated effect of simvastatin in delaying progression of an advanced form of multiple sclerosis is not related to its effect on cholesterol levels, a study published in PNAS has shown.
The blood pressure therapy isradipine does not slow disease progression in people with early-stage Parkinson’s disease, findings presented at the American Academy of Neurology Annual Meeting have shown.